Trial Title:
"cindilizumab + Bevacizumab + Coenzyme I for Injection" in Unresectable Hepatocellular Carcinoma
NCT ID:
NCT06590844
Condition:
Unresectable Hepatocellular Carcinoma
Conditions: Official terms:
Carcinoma
Carcinoma, Hepatocellular
Study type:
Interventional
Study phase:
Phase 4
Overall status:
Active, not recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
Injectable coenzyme I
Description:
On the first day, we will treat patients with Tybo Sulsintilimab ® 200mg IV and Dalutin ®
Bevacizumab 15mg/kg IV every 21 days. The first to third days were treated with
injectable coenzyme I, 100mg/day IV, every 21 days as a cycle.
Arm group label:
experimental group
Summary:
This study is a single-arm, single-center, non-randomized, open-label study. A total of
37 patients with locally advanced or metastatic HCC who have not received systemic
therapy, are not suitable for radical surgical resection or local treatment, or have
disease progression after surgical resection or local treatment, the efficacy and safety
of "cindilizumab + bevacizumab + coenzyme I for injection" are initially explored.
Detailed description:
1. Background According to the latest global cancer burden data for 2020 released by
the World Health Organization Agency for International Research on Cancer (IARC),
about 390,000 people die from liver cancer every year, accounting for 47 percent of
the global liver cancer deaths. As the second mortality malignant tumor in China,
the five-year survival rate is only 14%. Based on the ORIENT-32 study, the first
PD-1 immunosuppressive combination therapy sindilizumab combined with bevacizumab
for the first-line treatment of patients with advanced liver cancer has been
officially approved by the National Drug Administration for the first-line treatment
of unresectable or metastatic liver cancer."Sindilizumab + bevacizumab" marks a
breakthrough in liver cancer immunotherapy with the combination of PD-1
immunosuppressive agents. However, clinical trial data showed that the response rate
of immunosuppressive agents in solid tumors was low (ORIENT-32 ORR of "Sindilizumab
+ bevacizumab" regimen was 25%) and susceptible to tolerance. Therefore, finding
effective efficacy predictive markers and combination therapy is an important method
to improve the effect of tumor immunotherapy and promote tumor precision
immunotherapy.
Coenzyme I (nicotinamide adenine dinucleotide, NAD+) Is a very important coenzyme in
biological redox reactions and plays a crucial role in various biological processes
including metabolism, senescence, cell death, DNA repair and gene
expression。NAD+Metabolic abnormalities are closely related to the occurrence and
development of many diseases, including cancer. On November 9,2020, Academician Wang
Hongyang's team published the title "NAD" on Cell Metabolism+metabolism maintains
inducible PD-L1 expression to drive tumor immune evasion " research paper, reveals the
NAD+Metabolism drives novel mechanisms of tumor immune escape by regulating immune
checkpoint PD-L1 expression, and is proposed by supplementing NAD+Novel strategies to
enhance therapeutic sensitivity of anti-PD-1 / PD-L1 antibodies[5]. Further studies found
that the anti-PD-1 antibody suppressed tumor burden by 42.2% in a model of Hep 1-6-CD38
immunotherapy administered NAD+The tumor burden suppression rate after the combination
therapy was 82.8%. In the primary tolerance model of Pan02 immunotherapy in pancreatic
cancer, the anti-PD-1 antibody suppressed tumor burden by only 18.6%, giving NAD+The
combined treatment tumor burden suppression rate was 64.7%. In both models
simultaneously, the NAD+The group alone did not promote tumor growth compared with the
control group. The study has important clinical implications to complement the NAD+A
combination regimen with anti-PD-1 / PD-L1 antibodies could provide a novel therapeutic
strategy for tumors resistant to immunotherapy.
2、Effectiveness evaluation indicators (primary efficacy indicators and secondary efficacy
indicators) Primary endpoint
- ORR as assessed by mRECIST 1.1 Selected secondary study endpoints and exploratory
endpoints
- Safety and tolerability
- DOR, DCR, PFS, TTP, OS, as assessed by mRECIST 1.1
- Conversion rate Safety evaluation index The incidence and severity of all adverse
events (AEs), treatment emergent adverse events (TEAEs), grade 3 or higher study
drug-related adverse events, serious adverse events (SAEs) were judged according to
CTCAE V5.0, and the clinical characteristics, severity, time of occurrence of any
adverse events were recorded, End time, duration, treatment measures, and outcomes,
and determine their relevance to treatment regimens.
3、Statistical Methods All statistical analyses will be performed in SAS 9.4 or
later. In general, continuous variables will be statistically described using the
number of cases, mean, median, standard deviation, minimum and maximum values;
Categorical and hierarchical variables will be statistically described using the
frequency and percentage of each category or grade, and missing values will not be
included in the calculation of percentages unless otherwise indicated. Unless
otherwise stated, all statistical tests will be performed using a two-sided test of
α = 0.05 with a two-sided 95% confidence interval (CI) calculated.
4、Statistical processing All statistical analyses will be performed using SAS 9.4 or
later. In general, continuous variables will be statistically described using the
number of cases, mean, median, standard deviation, minimum and maximum values;
Categorical and hierarchical variables will be statistically described using the
frequency and percentage of each category or grade, and missing values will not be
included in the calculation of percentages unless otherwise indicated. Unless
otherwise stated, all statistical tests will be performed using a two-sided test of
α = 0.05 with a two-sided 95% confidence interval (CI) calculated.
5、Data security monitoring The clinical study will develop a data security
monitoring plan according to the size of the risk. All adverse events are recorded
in detail, properly handled and tracked until properly resolved or the condition is
stable, and serious adverse events and unexpected events are reported to the ethics
committee, competent authorities and drug regulatory departments in a timely manner
in accordance with regulations; The principal investigator conducted a systematic
review of all adverse events on a regular basis, and convened investigator meetings
to assess the risks and benefits of the study if necessary; Double-blind trials can
be urgently unblinded if necessary to ensure the safety and rights of subjects; For
studies with greater than minimal risk, an independent data monitor will be assigned
to monitor the study data, and for high-risk studies, an independent data safety
monitoring committee will be established to monitor the accumulated safety data and
efficacy data to make recommendations on whether to proceed with the study.
6、Ethics of clinical research Clinical studies will follow the Declaration of
Helsinki and other relevant regulations of the World Medical Assembly. The study can
only be carried out after the approval of the study by the ethics committee before
the start of the study. Before each subject is enrolled in this study, the
investigator has the responsibility to fully and comprehensively introduce the
purpose, procedures and possible risks of this study to the subject or his agent,
and sign a written informed consent form, and the subject should be let know that
they have the right to withdraw from this study at any time, and the informed
consent should be retained as a clinical study document for future reference. The
privacy and confidentiality of the subjects will be protected during the study.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
1. Histological/cytologically confirmed hepatocellular carcinoma, or cirrhosis of the
liver meets the American Association for the Study of Liver Diseases (AASLD)
clinical diagnostic criteria for hepatocellular carcinoma.
2. 18 years old≤ age ≤ 80 years old
3. ECOG PS 0-1 points, Child-Pugh score ≤7 points.
4. The 2022 edition of the Guidelines for the Diagnosis and Treatment of Liver Cancer
of the National Health Commission of China is stage IIb and above.
5. Have not received systemic anti-tumor therapy for HCC before the first dose
(enrollment is allowed more than 6 months after the end of postoperative adjuvant
chemotherapy), and enrollment is allowed 28 days after the end of TACE treatment.
6. Have adequate organ and bone marrow function. The laboratory test values within 7
days prior to enrollment meet the following requirements:
1. Routine blood count: absolute neutrophil count (ANC) ≥1.5× 109/L; Platelet
count (PLT) ≥ 75×10 9/L; Hemoglobin content (HGB) ≥ 9.0 g/dL.
2. Liver function: serum total bilirubin (TBIL) ≤2× upper limit of normal (ULN);
alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤5×ULN;
serum albumin≥ 28 g/L; Alkaline phosphatase (ALP) ≤5×ULN.
3. Renal function: serum creatinine (Cr) ≤ 1.5× ULN or creatinine clearance (CCr)
≥ 50mL/min; Patients with a urine protein ≥ 2+ should have a 24-hour urine
collection and a 24-hour urine protein quantification <1 g.
4. Coagulation function: International normalized ratio (INR) and activated
partial thromboplastin time (APTT) ≤ 1.5 times ULN.
7. Patients with acute or chronic active hepatitis B or hepatitis C infection,
hepatitis B virus (HBV) DNA less than 2000IU/ml or 10 copies/ml; Hepatitis C virus
(HCV) RNA is less than 1000 copies/ml.
Agree to participate in this clinical trial and sign a written informed consent form..
Exclusion Criteria:
1. Previously confirmed fibrolamellarhepatocellular carcinoma, sarcomatoid
hepatocellular carcinoma, cholangiocarcinoma and other components previously
confirmed by histology/cytology.
2. Have a history of hepatic encephalopathy, or have a history of liver
transplantation.
3. The portal vein trunk cancer thrombus involves the contralateral portal vein branch
at the same time, or the superior mesenteric vein and inferior vena cava cancer
thrombus at the same time..
4. Pleural effusion, ascites, and pericardial effusion that need to be drained with
clinical symptoms.
5. Hepatitis B surface antigen (HbsAg) is positive at the same time as anti-HCV
antibodies.
6. There are central nervous system metastases.
7. HIV infection.
8. Gastroscopy showed positive red sign of esophageal and gastric varices.
9. Women who are pregnant or preparing to become pregnant or breastfeeding.
10. Those who are known to be allergic to coenzyme I and its components or have serious
adverse reactions.
11. Those who have participated in other clinical trials within 3 months before
participating in this trial.
12. In the judgment of the investigator, the patient is unable to complete this study or
is unable to comply with the requirements of this study.
13. Participating in other interventional clinical trials.
Gender:
All
Minimum age:
18 Days
Maximum age:
80 Days
Healthy volunteers:
No
Locations:
Facility:
Name:
AnhuiI Provincial Hospital
Address:
City:
Hefei
Zip:
230000
Country:
China
Start date:
December 19, 2023
Completion date:
March 2026
Lead sponsor:
Agency:
Anhui Provincial Hospital
Agency class:
Other
Source:
Anhui Provincial Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06590844
